GEN News Highlights

Micronics has obtained the right to to make, have made, use, and sell products that incorporate Biosearch Technologies’ fluorophores and quencher dyes for nucleic acid assays. Under the terms of the worldwide license, Biosearch has granted Micronics royalty-free use of certain chemistries for inclusion in the latter’s infectious disease tests for sale in underdeveloped countries.

Biosearch’s line of fluorophores and quenchers, including the Black Hole Quencher (BHQ), CAL Fluor, and Quasar dye technologies, will be used by Micronics in conjunction with the molecular beacons probe technology that Micronics licensed from PHRI Properties.

The BHQ dyes are used for fluorescence-quenched probe applications in many nucleic acid assay testing methods. Most recently, the Centers for Disease Control and Prevention selected a BHQ dye as the core detection technology for use in the H1N1 real-time PCR test for distribution among public health and other qualified labs worldwide.

Micronics is advancing a family of near-patient, point-of-care molecular tests for infectious disease diagnosis and forensic testing. These tests employ Micronics’ microfluidics technologies, which enable substantial reductions in both the volume of a sample taken from a patient and the reagents required to perform a nucleic acid amplification assay, the company says. Micronics’ portfolio includes tests for Shiga toxin producing E. coli, malaria, and respiratory disease panels.

By incorporating molecular beacons with Biosearch fluorophores and BHQ dyes, Micronics’ test cartridges can perform either single or multiplex pathogen detection. Each test cartridge will contain all the required test reagents for ease of use and nonrefrigerated storage. The cartridge is processed by a lightweight, low-cost, battery or mains-powered instrument with software connectivity. Micronics’ tests are reportedly designed to provide a result in under 30 minutes, directly from sample acquisition in the sealed disposable test cartridge.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

Be sure to take the GEN Poll

Climate Change

How would you describe the researchers response to the 2°C global temperature target?

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

They are right on the mark. A 2°C global temperature rise will push us further over the edge. We have to set a lower target.

45.5%

A 2°C global temperature rise is a reasonable target on which to focus in order to diminish the impact of climate change.

9.1%

We have already gone beyond the threshold for getting a handle on climate change. So now we just need to learn how to adapt to the inexorable climatic changes with which we will have to deal going forward.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.